

Lucia Brodosi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6097479/lucia-brodosi-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

416
citations

12
h-index

20
g-index

26
ext. papers

623
ext. citations

4.2
avg, IF

4
L-index

#	Paper	IF	Citations
23	Long-term weight loss maintenance for obesity: a multidisciplinary approach. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016 , 9, 37-46	3.4	116
22	Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease. <i>Clinical Nutrition</i> , 2021 , 40, 1330-1337	5.9	41
21	Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?. <i>Liver Transplantation</i> , 2010 , 16, 964-73	4.5	40
20	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021 , 372, m4747	5.9	31
19	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018 , 69, 1155-1163	13.4	25
18	Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. <i>PLoS ONE</i> , 2013 , 8, e65327	3.7	24
17	Bone marrow derived stem cells for the treatment of end-stage liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9098-105	5.6	23
16	Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. <i>Digestive Diseases</i> , 2016 , 34 Suppl 1, 3-10	3.2	19
15	Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. <i>Digestive and Liver Disease</i> , 2015 , 47, 1059-66	3.3	18
14	NAASH: A glance at the landscape of pharmacological treatment. <i>Annals of Hepatology</i> , 2016 , 15, 673-81	3.1	18
13	A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score. <i>Liver International</i> , 2015 , 35, 184-91	7.9	16
12	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <i>Nutrients</i> , 2019 , 11,	6.7	14
11	Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 127-135	4.2	8
10	Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3912-20	5.6	5
9	The Effect of Liraglutide on EBlockade for Preventing Variceal Bleeding: A Case Series. <i>Annals of Internal Medicine</i> , 2020 , 173, 404-405	8	4
8	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. <i>Liver International</i> , 2021 , 41, 731-742	7.9	4
7	Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. <i>Annals of Hepatology</i> , 2014 , 13, 293-296	3.1	3

6	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. <i>Current Pharmaceutical Design</i> , 2020 , 26, 1110-1118	3.3	3
5	Maternal PKU: Defining phenylalanine tolerance and its variation during pregnancy, according to genetic background. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 977-983	4.5	1
4	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. <i>Italian Journal of Medicine</i> , 2011 , 5, 82-89	0.5	1
3	NEUROD1 mutation in an Italian patient with maturity onset diabetes of the young 6: a case report. <i>BMC Endocrine Disorders</i> , 2021 , 21, 202	3.3	0
2	Obesity and NAFLD: Same Problem? 2020 , 1-14		
1	Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-5	4	